Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Alopecia Areata: Work-up and Treatment
Description
In a presentation on alopecia areata, the speaker emphasizes practical approaches to treatment, focusing on emerging therapies such as JAK inhibitors. The discussion highlights the importance of understanding different treatment options, the significance of shared decision-making with patients, and the nuances of defining severity in alopecia areata. The speaker outlines a therapeutic ladder starting with foundational treatments, such as systemic corticosteroids and topical immunotherapy, and encourages stacking these with supplemental treatments like JAK inhibitors for better outcomes. The talk includes various patient case studies to illustrate different decision-making processes regarding JAK inhibitors, emphasizing that not all patients with alopecia areata are suitable candidates for these medications. The speaker also addresses the importance of diagnosing accurately and considering alternative treatments for patients who cannot take JAK inhibitors. Furthermore, there's a look towards future therapies, including OX40 inhibitors, which may offer new hope for patients experiencing alopecia areata. The session ends with an invitation to a summer Hair Health Summit for further education on the topic.
View moreConclusions
- Alopecia areata treatments have advanced significantly, with notable success in repurposing existing medications leading to FDA approval of multiple JAK inhibitors.
- JAK inhibitors are not typically used as first-line treatments for alopecia areata, and their selection depends on patient access and individual circumstances.
- Combination therapy with JAK inhibitors and other treatments can enhance regrowth outcomes for patients with alopecia areata.
- Patients should be informed that it may take 3 to 6 months or longer to observe hair regrowth with JAK inhibitors, and any regrowth may not be durable without ongoing treatment.
- Precautions are necessary for patients with a history of malignancy, thromboembolic disorders, or cardiac disease when considering JAK inhibitors.
- Severity assessment using the SALT score is important for determining treatment eligibility, but psychosocial impact and other factors should also be considered.
- Not all patients will respond to JAK inhibitors, highlighting the importance of individualized treatment plans and shared decision-making between clinicians and patients.
- Emerging treatments, including OX40 inhibitors, represent future directions for enhancing therapies for alopecia areata beyond current JAK inhibitors.
- Xing L, et. al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014
- Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014
- David, E ., Shokrian, N ., Del Duca, E. et al. Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study. Arch Dermatol Res 2024
- NandyMazumdar M, Liu Y, Yu Ekey M, Chowdhury A, Angelov M, Ungar B, Estrada Y, Guttman-Kim M, Del Duca E, Dahabreh D, Lozano-Ojalvo D, Carroll B, Manson M, Bose S, Gour D, Yassky E. Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds. Allergy. 2024
- Croft, M ., Esfandiari, E ., Chong, C. et al. OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. Am J Clin Dermatol 2024